查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2017985

載體篩檢市場：按檢測類型、技術、載體類型、應用和最終用戶分類－2026-2032年全球市場預測

Carrier Screening Market by Test Type, Technology, Carrier Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，病毒攜帶者篩檢市場價值將達到 33.1 億美元，到 2026 年將成長至 34.9 億美元，到 2032 年將達到 49.7 億美元，複合年成長率為 5.95%。

主要市場統計數據
基準年 2025 33.1億美元
預計年份：2026年 34.9億美元
預測年份 2032 49.7億美元
複合年成長率 (%) 5.95%

全面概述攜帶者篩檢趨勢，並將其置於患者診療路徑、臨床決策因素和檢查室策略重點的背景下進行分析。

攜帶者篩檢正從一項專門的臨床服務發展成為生殖醫學和公共衛生管理的重要組成部分。分子技術的進步，加上不斷更新的臨床指南和患者意識的提高，正推動篩檢範圍從傳統的高風險族群擴展到更廣泛的群體。因此，臨床檢查室、婦產科診所、遺傳諮詢服務機構和保險公司等各方相關人員正在重新評估服務組合、診療路徑和夥伴關係模式，以最佳化臨床價值和營運永續性。

對正在重新定義攜帶者篩檢交付模式的技術、臨床、監管和商業性轉折點進行了清晰的概述。

攜帶者篩檢生態系統正受到技術、臨床實踐、監管和商業模式等一系列變革性變化的影響而重塑。次世代定序和數位PCR技術的成熟使得更廣泛的檢測項目和更高的分析靈敏度成為可能，從而引發了關於檢測範圍以及臨床實用結果與意外觀察之間平衡的更積極討論。隨著技術進步降低檢體成本並提高處理能力，檢查室正在重新思考其檢測項目，並投資於生物資訊學流程，以支持突變解讀和大規模報告。

專家評估近期美國關稅變化對整個承運商篩檢供應鏈、籌資策略和業務永續營運。

2025年美國關稅政策的變化給了攜帶者篩檢價值鏈中的實驗室、製造商和經銷商的營運成本會計引入新變數。進口試劑、耗材和專用設備的關稅將推高實驗室投入的直接成本，這可能會促使採購團隊重新評估籌資策略和與供應商的關係。雖然實驗室通常會自行承擔增加的成本以維持價格競爭力，但持續的成本上漲可能迫使其調整價格，並與支付方和醫療服務提供者重新談判服務合約。

詳細的細分分析揭示了測試類型、技術、應用、職業分類和最終用戶概況如何影響戰略選擇。

在攜帶者篩檢生態系統中，深入的市場區隔對於理解臨床需求、技術能力和最終用戶需求之間的交集至關重要。基於檢測類型構建的市場分析突顯了「擴展攜帶者檢測組合」（旨在提高多個基因的診斷率）、「單基因檢測」（針對特定臨床場景或遺傳性性突變）以及「靶向攜帶者檢測組合」（針對特定疾病或人群特異性突變）之間的關鍵差異。這些差異會影響諮詢的複雜性、報告架構和檢查室工作流程設計。

區域比較分析解釋了政策、資金籌措模式和醫療保健基礎設施如何造成不同的採用和商業化路徑。

區域趨勢正以意義深遠且往往各具特色的方式影響政策、報銷和部署路徑，為部署策略和夥伴關係模式提供了重要啟示。在美洲，人們對擴大檢測項目範圍和整合諮詢服務的興趣日益濃厚，這主要得益於對臨床效用、支付方合作以及檢查室規模運營的高度重視。同時，公共和私人支付方的框架也在影響檢測的報銷和取得。北美檢查室網路也是報告標準和數據共用創新的主要推動力，影響著供應商和臨床合作夥伴對互通性功能的設計。

策略競爭評估概述了成熟企業、專業測試實驗室、試劑合作夥伴和新興創新者如何塑造市場結構和夥伴關係關係。

攜帶者篩檢領域的競爭動態反映了成熟診斷設備製造商、專業檢測網路、試劑和耗材供應商以及專注於新型檢測方法和服務模式的顛覆性Start-Ups之間的互動。成熟的平台提供者通常強調整合定序硬體、檢驗的檢測方法和資訊學的整合解決方案，使實驗室能夠在保持可重複性和符合監管要求的同時擴展業務規模。與此同時，獨立實驗室和專業實驗室則在快速週轉時間、與臨床醫生的良好關係以及提供針對特定人群和臨床需求的客製化報告方面展開競爭。

為檢查室、臨床和商業領域的領導者提供有針對性的、實用的行動指南，以確保營運韌性並最大限度地提高臨床價值。

產業領導者可以透過採取一系列切實可行、以結果為導向的措施，將競爭資訊轉化為競爭優勢，從而應對臨床、營運和商業性的挑戰。這包括優先投資於能夠縮短週轉時間、增強突變分析能力的技術和資訊學，從而提高臨床醫生的信心和患者體驗。同時，他們也制定靈活的籌資策略和多供應商契約，以減輕供應鏈中斷和關稅相關的成本壓力，同時確保品質和業務連續性。

透明的調查方法聲明，解釋了分析所依據的資料來源、相關人員的參與、分析安全措施和局限性。

本報告的研究整合了多方面的證據，對攜帶者篩檢趨勢進行了嚴謹透明的分析。主要研究包括對臨床檢查室管理人員、遺傳諮詢師、保險公司和供應商進行結構化訪談，以了解實際操作、實施障礙和策略重點。除訪談外，研究還查閱了臨床指南、監管公告和同行評審文獻，以對照當前的護理標準和科學共識來佐證研究結果。

一份前瞻性總結，整合了臨床實踐、營運韌性和策略投資見解，用於職業篩檢。

攜帶者篩檢正處於轉折點，技術能力、不斷發展的臨床實踐和商業性壓力在此交匯，既帶來了機遇，也帶來了挑戰。如何在效用與諮詢負擔之間取得平衡，如何滿足支付方對價值證明的需求，以及如何確保穩健的供應鏈等營運需求，這些都是決定競爭成敗的關鍵因素。隨著檢測日益融入常規生殖醫學，那些投資於可擴展資訊系統、以臨床醫生為中心的報告系統和多元化籌資策略的機構將佔據主導地位。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 病毒攜帶者篩檢市場：檢測類型

  • 擴充載板
  • 單基因檢測
  • 目標載體面板

第9章 載體篩檢市場：依技術分類

  • 微陣列
  • 次世代定序
    • 目標序列
    • 全EXOME定序
  • 聚合酵素鏈鎖反應
    • 數位PCR
    • 定量PCR
  • 桑格定序

第10章 依承運商類型分類的承運商篩檢市場

  • 體染色體隱性遺傳疾病
  • X連鎖疾病

第11章 載體篩檢市場：依應用領域分類

  • 懷孕前篩檢
  • 產前篩檢

第12章 載體篩檢市場：依最終用戶分類

  • 醫院檢查室
  • 獨立檢測實驗室
  • 專科診所

第13章 病毒攜帶者篩檢市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 載體篩檢市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 載體篩檢市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國承運人篩檢市場

第17章：中國載體篩檢市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agilent Technologies, Inc.
  • BGI Genomics Co., Ltd.
  • Eurofins Scientific SE
  • Fulgent Genetics, Inc.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings
  • Myriad Genetics, Inc.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • OPKO Health, Inc.
  • PerkinElmer, Inc.
  • Quest Diagnostics Incorporated
Product Code: MRR-034230D3E2DE

The Carrier Screening Market was valued at USD 3.31 billion in 2025 and is projected to grow to USD 3.49 billion in 2026, with a CAGR of 5.95%, reaching USD 4.97 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.31 billion
Estimated Year [2026] USD 3.49 billion
Forecast Year [2032] USD 4.97 billion
CAGR (%) 5.95%

A comprehensive contextual overview of carrier screening dynamics that frames patient pathways, clinical decision drivers, and laboratory strategic priorities

Carrier screening is evolving from a specialized clinical service to an essential component of reproductive care and population health management. Advances in molecular technologies, coupled with shifting clinical guidelines and growing patient awareness, have broadened the use cases for screening beyond traditional high-risk groups. As a result, stakeholders across clinical laboratories, obstetrics and gynecology practices, genetic counseling services, and payer organizations are reevaluating service portfolios, care pathways, and partnership models to optimize clinical value and operational sustainability.

Clinicians now navigate increasingly complex choices between expanded carrier panels and more targeted assays, seeking to balance diagnostic yield, turn-around time, and counseling burden. Laboratories are investing in automation and informatics to scale throughput while maintaining analytic quality, and payers are scrutinizing evidence of clinical utility and downstream cost implications. Patient expectations for rapid, transparent results and integrated counseling further influence how providers design service experiences. Taken together, these forces set the stage for strategic decisions that prioritize interoperability, evidence generation, and patient-centered delivery models.

An incisive synthesis of the technological, clinical, regulatory, and commercial inflection points that are redefining carrier screening delivery models

The carrier screening ecosystem is being reshaped by a set of transformative shifts that extend across technology, clinical practice, regulation, and commercial models. Technological maturation of next-generation sequencing and digital PCR has enabled broader panels and higher analytic sensitivity, which in turn drives debate about scope of testing and the balance between actionable results and incidental findings. As technology lowers per-sample costs and improves throughput, laboratories are reassessing test menus and investing in bioinformatics pipelines that support variant interpretation and reporting at scale.

Parallel changes in clinical practice emphasize prevention and preconception planning, prompting integration of carrier screening into routine reproductive care pathways. This shift is supported by more robust professional guidance recommending earlier and more universal consideration of carrier testing. In response, genetic counseling delivery models are diversifying to include remote and asynchronous modalities, addressing capacity constraints while maintaining quality of patient education.

Commercially, payers and employers are demanding clearer demonstrations of clinical utility and value, accelerating the development of real-world evidence and health-economic analyses. Regulatory attention to laboratory-developed tests and data privacy requirements is increasing, creating a more complex compliance landscape. Meanwhile, the competitive environment is fostering strategic partnerships between sequencing platforms, diagnostic laboratories, and healthcare systems, enabling vertical integration and new service bundles that combine testing, counseling, and care coordination. These cumulative shifts require stakeholders to adapt governance, investment, and go-to-market strategies to remain resilient and relevant.

An expert appraisal of how recent United States tariff changes are influencing supply chains, procurement strategies, and operational resilience across carrier screening

Changes to United States tariff policy in 2025 have introduced new variables into the operational calculus for laboratories, manufacturers, and distributors within the carrier screening value chain. Tariff-induced cost pressures on imported reagents, consumables, and specialized instrumentation can raise the direct cost of testing inputs, prompting procurement teams to reexamine sourcing strategies and supplier relationships. In many instances, laboratories may absorb incremental costs to remain price-competitive, but sustained increases could necessitate price adjustments or renegotiation of service contracts with payers and providers.

Beyond immediate input costs, tariffs can catalyze strategic shifts such as localization of supply chains, diversification of vendor rosters, and investment in alternative technologies that are less reliant on affected imports. Manufacturers and distributors may respond by accelerating regional production capacity or by redesigning product kits to minimize tariff exposure. These responses have implications for lead times, quality assurance, and inventory management, and can introduce short-term volatility in availability of critical reagents.

Operationally, laboratories may face trade-offs between maintaining broad test menus and consolidating panels to optimize throughput and reagent utilization. Payer negotiation dynamics could intensify as third-party payers scrutinize unit costs and utilization patterns in the context of higher supplier prices. Over the medium term, tariffs can also influence merger and acquisition activity, as consolidation becomes a mechanism to achieve scale, secure supply chains, and mitigate unit cost pressures. Stakeholders that proactively model tariff scenarios, strengthen procurement flexibility, and engage suppliers in collaborative contingency planning will be better positioned to sustain service continuity and protect margins without compromising clinical quality.

A granular segmentation narrative that clarifies how test type, technology, application, carrier classification, and end-user profiles shape strategic choices

Insightful segmentation is essential to understand where clinical need, technological capability, and end-user demand intersect within the carrier screening ecosystem. When market analysis is structured based on test type, important distinctions emerge between Expanded Carrier Panel offerings that aim to increase diagnostic yield across many genes, Single Gene Tests that target defined clinical scenarios or familial variants, and Targeted Carrier Panels optimized for focused conditions or population-specific variants. These differences influence counseling complexity, reporting frameworks, and laboratory workflow design.

Segmentation by technology highlights the divergent roles of Microarray platforms, Next Generation Sequencing approaches, Polymerase Chain Reaction methods, and Sanger Sequencing. Next Generation Sequencing is increasingly segmented further into Targeted Sequencing for gene panels and Whole Exome Sequencing for broader diagnostic exploration, each presenting unique interpretive and data management challenges. Polymerase Chain Reaction is used in multiple configurations, with Digital PCR offering high sensitivity for low-frequency variants and Quantitative PCR supporting copy-number and dosage analyses. Each technological choice carries implications for throughput, turn-around time, capital expenditure, and downstream bioinformatics investment.

Applications segment the market between Preconception Screening, where decisions can alter reproductive planning, and Prenatal Screening, which often requires rapid results and integrated counseling pathways. Carrier type differentiates needs for Autosomal Recessive Disorders, where both parental carrier status matters, and X Linked Disorders, which raise distinct counseling considerations, especially for female carriers. Finally, end-user segmentation across Hospital Laboratories, Independent Laboratories, and Specialty Clinics clarifies procurement behavior, volume expectations, and service integration models. Understanding how these segmentation axes interact enables stakeholders to prioritize product development, clinical partnerships, and tailored service propositions that align with the unique needs of each cohort.

A comparative regional analysis that explains how policy, funding models, and healthcare infrastructure drive divergent adoption and commercialization pathways

Regional dynamics shape policy, reimbursement, and adoption pathways in meaningful and often divergent ways, with implications for deployment strategies and partnership models. In the Americas, a strong emphasis on clinical utility, payer engagement, and laboratory-scale operations drives interest in expanded panels and integrated counseling services, while public and private payer frameworks influence test reimbursement and access. North American laboratory networks are also prominent drivers of innovation in reporting standards and data sharing, which affects how vendors and clinical partners design interoperability features.

Across Europe, Middle East & Africa, heterogeneous regulatory environments and variable healthcare funding models create a patchwork of adoption rates and testing pathways. Many European health systems favor centralized laboratory services and evidence-based reimbursement assessments, which can slow adoption of certain panels but also create opportunities for demonstrations of cost-effectiveness and clinical outcome improvements. Regulatory harmonization efforts and cross-border collaborations are increasingly important for manufacturers looking to scale operations across multiple jurisdictions in this region.

In the Asia-Pacific region, rapid expansion of diagnostic infrastructure, public health initiatives focused on genetic disease prevention, and growing private laboratory sectors combine to create dynamic demand for carrier screening. Diverse population genetics profiles and varying levels of reimbursement drive both population-tailored panels and commercial models that emphasize point-of-care integration and direct laboratory partnerships with prenatal care providers. Across all regions, differences in data privacy regulations, genetic counseling capacity, and supply chain logistics necessitate localized go-to-market approaches that account for cultural, clinical, and policy nuances.

A strategic competitive assessment outlining how incumbents, specialty laboratories, reagent partners, and emerging innovators are shaping market structure and partnerships

Competitive dynamics in the carrier screening space reflect the interplay between established diagnostic manufacturers, specialized laboratory networks, reagent and consumables suppliers, and disruptive start-ups focused on novel assays or service models. Established platform providers often emphasize integrated solutions that combine sequencing hardware, validated assays, and informatics, enabling labs to scale while maintaining reproducibility and regulatory compliance. At the same time, independent and specialty laboratories compete on rapid turn-around times, clinician relationships, and customized reporting that addresses specific population or clinical needs.

Suppliers of reagents and consumables play a strategic role by enabling cost-per-test improvements and flexible kit configurations. Their decisions around manufacturing location, supply agreements, and product design can materially affect laboratory operations, especially in periods of supply chain disruption. Emerging companies are differentiating through innovations in variant interpretation software, automated reporting, and tele-genetics platforms that expand counseling capacity and improve patient engagement.

Across the competitive landscape, strategic partnerships and co-development agreements are common, as players seek to combine clinical reach with technological capability. Mergers and acquisitions remain a viable route for both vertical integration and rapid access to new markets or expertise. For stakeholders evaluating partnerships or investments, the most relevant indicators of long-term success include validated clinical workflows, interoperability of data systems, regulatory readiness, and a demonstrable commitment to evidence generation and clinician education.

A pragmatic playbook of targeted actions that enable laboratory, clinical, and commercial leaders to secure operational resilience and scale clinical value

Industry leaders can convert market intelligence into competitive advantage by adopting a set of practical, outcome-focused actions that address clinical, operational, and commercial imperatives. Prioritize investment in technologies and informatics that reduce turn-around time and enhance variant interpretation capacity, thereby improving clinician confidence and patient experience. Simultaneously, develop flexible procurement strategies and multi-supplier agreements to mitigate supply chain disruptions and tariff-related cost pressures while safeguarding quality and continuity.

Strengthen relationships with clinicians and genetic counselors through co-created educational materials and streamlined reporting formats that reduce interpretation burden and facilitate shared decision-making. Engage payers early with real-world evidence initiatives that document clinical utility, reproductive outcomes, and downstream cost impacts, thereby creating a stronger value case for coverage and preferred-provider arrangements. Explore partnership models that bundle testing with counseling and care coordination, unlocking differentiated service propositions and enabling integrated reimbursement dialogues.

Finally, embed governance for data privacy and variant reclassification into operational workflows, ensuring compliance with evolving regulatory expectations and maintaining patient trust. Consider strategic options such as selective consolidation, targeted M&A, or joint ventures to attain scale, diversify service portfolios, and accelerate entry into new geographies. These measured, tactical steps will help organizations navigate near-term disruptions while positioning them for sustainable growth.

A transparent methodological statement explaining data sources, stakeholder engagement, analytical safeguards, and limitations that underpin the analysis

The research underpinning this report integrates multiple evidence streams to produce a rigorous and transparent analysis of carrier screening dynamics. Primary research consisted of structured interviews with clinical laboratory leaders, genetic counselors, payers, and technology vendors to capture operational practices, adoption barriers, and strategic priorities. These interviews were supplemented by a review of clinical guidelines, regulatory announcements, and peer-reviewed literature to ground findings in current standards of care and scientific consensus.

Secondary data sources included technical specifications and product documentation for major sequencing and PCR platforms, industry white papers on supply chain and manufacturing trends, and policy documents that detail reimbursement and regulatory frameworks across jurisdictions. Where relevant, case studies were examined to illustrate successful deployment models, payer engagement strategies, and laboratory workflow optimizations. Methodological safeguards included triangulation across data sources, validation of themes through multiple stakeholder perspectives, and iterative synthesis to ensure internal consistency and reproducibility of conclusions.

Limitations of the research are acknowledged and include variability in regional policy implementation and the evolving nature of tariff policy, which may impact short-term operational decisions. To mitigate these limitations, the analysis emphasizes structural drivers and scenario-based implications rather than short-term numeric projections, enabling readers to apply insights to context-specific planning and risk assessment.

A forward-looking synthesis that consolidates implications for clinical practice, operational resilience, and strategic investment in carrier screening

Carrier screening sits at an inflection point where technological capability, clinical practice evolution, and commercial pressures converge to create both opportunity and complexity. The balance between expanded panel utility and counseling burden, the imperative to demonstrate value to payers, and the operational need to secure resilient supply chains are recurring themes that will determine competitive success. Organizations that invest in scalable informatics, clinician-centric reporting, and diversified procurement strategies will be positioned to lead as testing becomes more integrated into routine reproductive care.

Regulatory and policy shifts will continue to influence market dynamics, and proactive engagement with payers and policymakers is critical to shape favorable reimbursement and access pathways. At the same time, thoughtful governance around data privacy, variant interpretation, and recontact obligations will sustain patient trust and support long-term adoption. The path forward favors stakeholders who combine clinical rigor with commercial agility, leveraging partnerships to expand reach while maintaining high standards of analytic validity and clinical relevance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Carrier Screening Market, by Test Type

  • 8.1. Expanded Carrier Panel
  • 8.2. Single Gene Test
  • 8.3. Targeted Carrier Panel

9. Carrier Screening Market, by Technology

  • 9.1. Microarray
  • 9.2. Next Generation Sequencing
    • 9.2.1. Targeted Sequencing
    • 9.2.2. Whole Exome Sequencing
  • 9.3. Polymerase Chain Reaction
    • 9.3.1. Digital PCR
    • 9.3.2. Quantitative PCR
  • 9.4. Sanger Sequencing

10. Carrier Screening Market, by Carrier Type

  • 10.1. Autosomal Recessive Disorders
  • 10.2. X Linked Disorders

11. Carrier Screening Market, by Application

  • 11.1. Preconception Screening
  • 11.2. Prenatal Screening

12. Carrier Screening Market, by End User

  • 12.1. Hospital Laboratories
  • 12.2. Independent Laboratories
  • 12.3. Specialty Clinics

13. Carrier Screening Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Carrier Screening Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Carrier Screening Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Carrier Screening Market

17. China Carrier Screening Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Agilent Technologies, Inc.
  • 18.6. BGI Genomics Co., Ltd.
  • 18.7. Eurofins Scientific SE
  • 18.8. Fulgent Genetics, Inc.
  • 18.9. Invitae Corporation
  • 18.10. Laboratory Corporation of America Holdings
  • 18.11. Myriad Genetics, Inc.
  • 18.12. Myriad Genetics, Inc.
  • 18.13. Natera, Inc.
  • 18.14. OPKO Health, Inc.
  • 18.15. PerkinElmer, Inc.
  • 18.16. Quest Diagnostics Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARRIER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CARRIER SCREENING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CARRIER SCREENING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CARRIER SCREENING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CARRIER SCREENING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARRIER SCREENING MARKET SIZE, BY CARRIER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CARRIER SCREENING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CARRIER SCREENING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CARRIER SCREENING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CARRIER SCREENING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CARRIER SCREENING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CARRIER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CARRIER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CARRIER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CARRIER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CARRIER SCREENING MARKET SIZE, BY EXPANDED CARRIER PANEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CARRIER SCREENING MARKET SIZE, BY EXPANDED CARRIER PANEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARRIER SCREENING MARKET SIZE, BY EXPANDED CARRIER PANEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CARRIER SCREENING MARKET SIZE, BY SINGLE GENE TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CARRIER SCREENING MARKET SIZE, BY SINGLE GENE TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CARRIER SCREENING MARKET SIZE, BY SINGLE GENE TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CARRIER SCREENING MARKET SIZE, BY TARGETED CARRIER PANEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CARRIER SCREENING MARKET SIZE, BY TARGETED CARRIER PANEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CARRIER SCREENING MARKET SIZE, BY TARGETED CARRIER PANEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CARRIER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CARRIER SCREENING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CARRIER SCREENING MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CARRIER SCREENING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CARRIER SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARRIER SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CARRIER SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARRIER SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CARRIER SCREENING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CARRIER SCREENING MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CARRIER SCREENING MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CARRIER SCREENING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CARRIER SCREENING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CARRIER SCREENING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CARRIER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARRIER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CARRIER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARRIER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CARRIER SCREENING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARRIER SCREENING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CARRIER SCREENING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARRIER SCREENING MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CARRIER SCREENING MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARRIER SCREENING MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CARRIER SCREENING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARRIER SCREENING MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CARRIER SCREENING MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CARRIER SCREENING MARKET SIZE, BY CARRIER TYPE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CARRIER SCREENING MARKET SIZE, BY AUTOSOMAL RECESSIVE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CARRIER SCREENING MARKET SIZE, BY AUTOSOMAL RECESSIVE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CARRIER SCREENING MARKET SIZE, BY AUTOSOMAL RECESSIVE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CARRIER SCREENING MARKET SIZE, BY X LINKED DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CARRIER SCREENING MARKET SIZE, BY X LINKED DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CARRIER SCREENING MARKET SIZE, BY X LINKED DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CARRIER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CARRIER SCREENING MARKET SIZE, BY PRECONCEPTION SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CARRIER SCREENING MARKET SIZE, BY PRECONCEPTION SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CARRIER SCREENING MARKET SIZE, BY PRECONCEPTION SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CARRIER SCREENING MARKET SIZE, BY PRENATAL SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CARRIER SCREENING MARKET SIZE, BY PRENATAL SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CARRIER SCREENING MARKET SIZE, BY PRENATAL SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CARRIER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CARRIER SCREENING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CARRIER SCREENING MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CARRIER SCREENING MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CARRIER SCREENING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CARRIER SCREENING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CARRIER SCREENING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CARRIER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CARRIER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CARRIER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CARRIER SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS CARRIER SCREENING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS CARRIER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS CARRIER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS CARRIER SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS CARRIER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS CARRIER SCREENING MARKET SIZE, BY CARRIER TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS CARRIER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS CARRIER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA CARRIER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA CARRIER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA CARRIER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA CARRIER SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA CARRIER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA CARRIER SCREENING MARKET SIZE, BY CARRIER TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA CARRIER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA CARRIER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA CARRIER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA CARRIER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA CARRIER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA CARRIER SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA CARRIER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA CARRIER SCREENING MARKET SIZE, BY CARRIER TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA CARRIER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA CARRIER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA CARRIER SCREENING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA CARRIER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA CARRIER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA CARRIER SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA CARRIER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA CARRIER SCREENING MARKET SIZE, BY CARRIER TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA CARRIER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA CARRIER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE CARRIER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE CARRIER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE CARRIER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE CARRIER SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE CARRIER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE CARRIER SCREENING MARKET SIZE, BY CARRIER TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE CARRIER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE CARRIER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST CARRIER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST CARRIER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST CARRIER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST CARRIER SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST CARRIER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST CARRIER SCREENING MARKET SIZE, BY CARRIER TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST CARRIER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST CARRIER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA CARRIER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA CARRIER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA CARRIER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA CARRIER SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA CARRIER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA CARRIER SCREENING MARKET SIZE, BY CARRIER TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA CARRIER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA CARRIER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC CARRIER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC CARRIER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC CARRIER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC CARRIER SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC CARRIER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC CARRIER SCREENING MARKET SIZE, BY CARRIER TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC CARRIER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC CARRIER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CARRIER SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN CARRIER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN CARRIER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN CARRIER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN CARRIER SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN CARRIER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN CARRIER SCREENING MARKET SIZE, BY CARRIER TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN CARRIER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN CARRIER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. GCC CARRIER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GCC CARRIER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. GCC CARRIER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. GCC CARRIER SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 141. GCC CARRIER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 142. GCC CARRIER SCREENING MARKET SIZE, BY CARRIER TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. GCC CARRIER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. GCC CARRIER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION CARRIER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION CARRIER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION CARRIER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION CARRIER SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION CARRIER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION CARRIER SCREENING MARKET SIZE, BY CARRIER TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION CARRIER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION CARRIER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS CARRIER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS CARRIER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS CARRIER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS CARRIER SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS CARRIER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS CARRIER SCREENING MARKET SIZE, BY CARRIER TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS CARRIER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS CARRIER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. G7 CARRIER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. G7 CARRIER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. G7 CARRIER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. G7 CARRIER SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 165. G7 CARRIER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 166. G7 CARRIER SCREENING MARKET SIZE, BY CARRIER TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. G7 CARRIER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. G7 CARRIER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. NATO CARRIER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. NATO CARRIER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. NATO CARRIER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. NATO CARRIER SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 173. NATO CARRIER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 174. NATO CARRIER SCREENING MARKET SIZE, BY CARRIER TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. NATO CARRIER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. NATO CARRIER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL CARRIER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES CARRIER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES CARRIER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES CARRIER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES CARRIER SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES CARRIER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES CARRIER SCREENING MARKET SIZE, BY CARRIER TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES CARRIER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES CARRIER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA CARRIER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA CARRIER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA CARRIER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA CARRIER SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA CARRIER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA CARRIER SCREENING MARKET SIZE, BY CARRIER TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA CARRIER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA CARRIER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)